Technology: Biorise®
Eurand’s Biorise technology enhances bioavailability by creating new physical entities (NPEs) with improved solubility profiles.
New Physical Entities (NPEs) are produced by breaking down the crystalline drug into nanocrystals and/or amorphous (noncrystalline) drug that is stabilized in a carrier system to maintain the drug in its activated form for the duration of its shelf life.
This approach creates a greater surface area to volume ratio that increases the intrinsic solubility and dissolution rate of poorly water-soluble drugs, thereby enhancing their rate and extent of absorption.
The Biorise technology can be applied to Class II compounds with solubilities in the range of <10 to 500 μg/mL.
Eurand has developed 2 distinct proprietary activation systems to create NPEs by converting drugs into their stabilized, thermodynamically activated state. These systems provide flexibility and allow the technology to be applied to a range of compounds with differing physicochemical characteristics.
The Biorise technology manufacturing process provides both time savings and cost efficiencies with its short cycle time, single processing step, batch consistency, and formulation stability.
Biorise Proprietary Activation Systems
Advantages of Biorise
- Increases solubility of Class II compounds
- Provides a faster onset of action, equivalent therapy at lower doses, and/or oral dosing of poorly soluble drug candidates
- Short manufacturing cycle time and single processing step
Eurand’s proprietary HEMA system equipment for Biorise 
Benchtop mills for small batch testing
The Biorise technology portfolio includes a number of granted patents that provide international coverage. There are also over 20 pending patent applications relating to this technology as we continue to innovate and build around this platform. In addition to our background IP, we are able to apply for patent coverage for the new formulations specific to our partners’ compounds, thus providing the potential to extend patent life beyond that of the compound.
Case Studies
More Information
For more information, contact Eurand at partners@eurand.com or +1-267-759-9340
contact Eurand +